SOHO 2023 | CRB-401 18-month follow-up: influence of T-cell profile on outcome of ide-cel treatment in myeloma
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, summarizes results from the post hoc 18-month follow-up of the Phase I CRB-401 study (NCT02658929) which investigated the efficacy and safety of idecabtagene vicleucel (ide-cel) treatment in patients with relapsed/refractory (R/R) multiple myeloma. Dr Lin comments on the longer progression-free survival (PFS) observed in patients whose T-cells showed naive stem cell-like characteristics and the influence of prior salvage therapies on T-cell profile. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bluebird Bio: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Legend: Consultancy; Juno: Consultancy; Celgene: Consultancy, Research Funding; Novartis: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Gamida Cell: Consultancy; Takeda: Research Funding; Vineti: Consultancy; Sorrento: Consultancy; Merck: Research Funding.
